V. Blatt

University of Padua — Italy

Medicine · Health Sciences

10h-index1.9kcitations19works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(18), Brain Metastases and Treatment(10), Histone Deacetylase Inhibitors Research(7), Epigenetics and DNA Methylation(3), Nanoplatforms for cancer theranostics(2)

Publications19 total

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Cancer Chemotherapy and Pharmacology·2009· 100 citedOpen Access
Recurrence pattern after concomitant radio-chemotherapy in newly diagnosed glioblastoma patients: Correlation with <i>MGMT</i> promoter methylation status
Journal of Clinical Oncology·2008
<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Journal of Clinical Oncology·2008· 820 citedOpen Access
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
Journal of Neuro-Oncology·2008· 78 cited
Long‐term results of a prospective study on the treatment of medulloblastoma in adults
Cancer·2007· 145 citedOpen Access
2507 POSTER Temozolomide (TMZ) concomitant to radiotherapy (RT) plus 12 cycles of maintenance chemotherapy in newly diagnosed GBM: is more better?
European Journal of Cancer Supplements·2007· 1 cited
2518 POSTER Prolonged maintenance chemotherapy with Temozolomide (TMZ) after concomitant treatment in newly diagnosed GBM: safety profile
European Journal of Cancer Supplements·2007· 1 cited
Should adult medulloblastoma patients at low risk receive adjuvant chemotherapy? Long-term results of a prospective study
Journal of Clinical Oncology·2007· 1 cited
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
British Journal of Cancer·2007· 210 citedOpen Access
Glioblastoma in the elderly: Current and future trends
Critical Reviews in Oncology/Hematology·2006· 39 cited
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
British Journal of Cancer·2006· 227 citedOpen Access
Prognostic factors for anaplastic astrocytomas
Journal of Neuro-Oncology·2006· 36 cited
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
Journal of Clinical Oncology·2006· 194 cited
Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: A phase II GICNO study
Journal of Clinical Oncology·2006· 4 cited
Is protracted low-dose temozolomide feasible in glioma patients?
Neurology·2006· 37 cited
Temozolomide (TMZ) for progressive primitive brain tumors: safety at 75 mg/m<sup>2</sup> a day for 21 days every 28: A GICNO (Italian Neuro-Oncology Group) study
Journal of Clinical Oncology·2005· 1 cited
Temozolomide (TMZ) for 21/28 days in patients with progressive glioblastoma (GBM): Preliminary results of phase 2 study of GICNO (Italian Neuro-Oncology Group).
Neuro-Oncology·2005
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
Journal of Clinical Oncology·2004· 5 cited
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
Journal of Clinical Oncology·2004· 1 cited

Frequent Co-authors

Alba A. Brandes(16), Enrico Franceschi(15), A. Tosoni(14), Mario Ermani(9), L. Scopece(7), Giovanni Cavallo(6), M. Ermani(6), Alicia Tosoni(5), Stefania Bartolini(5), Lara Maria Pasetto(5), Roberta Bertorelle(4), Lucio Crinò(4), Michele Reni(4), Sara Lonardi(3), Claudio Ghimenton(3), Linda Nicolardi(3), A.A. Brandes(3), Annalisa Pession(2), Giovanni Tallini(2), F. Spagnolli(2)